3 completed, 3 recruiting, 2 terminated. 6 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 3 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow young TIL: new trials by email Literature Review of young TIL trials Research Report on young TIL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab - Metastatic Melanoma | Early Phase 1 | Terminated | Yale University | 6 | 2018-02-06 | 2022-07-25 |
| A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab young TIL, Pembrolizumab, Aldesleukin - Melanoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 53 | 2015-12-04 | 2026-08-20 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Aldesleukin, Fludarabine, Cyclophosphamide - Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 85 | 2014-10-23 | 2026-10-20 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Aldesleukin, Fludarabine, Cyclophosphamide - Metastatic Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2013-12-12 | 2023-01-18 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Fludarabine, Cyclophosphamide, Young TIL - Cervical Cancer, Oropharyngeal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2012-04-13 | 2018-03-07 |
| Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Vemurafenib, Young TIL, Cyclophosphamide - Metastatic Cancer, Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2012-04-09 | 2019-11-21 |
| Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... Aldesleukin, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Skin Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 102 | 2011-03-24 | 2025-12-19 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide - Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer | Phase 2 | Recruiting | National Cancer Institute (NCI) | 332 | 2010-08-26 | 2026-10-23 |
Melanoma (5) · Neoplasm Metastasis (2) · Skin Neoplasms (2) · Adenocarcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Oropharyngeal Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (7) · Yale University (1)
United States (8)
Steven A Rosenberg, M.D. (4) · Stephanie L Goff, M.D. (2) · James C Yang, M.D. (1)
PMID 30714987, PMID 24812403, PMID 25432172, PMID 25823737, PMID 35104158, PMID 38816232, PMID 40169866